Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release - Seite 2

• Following the much higher increase in demand for TWYMEEG than expected, and temporarily tight inventories, Sumitomo Pharma’s diligent work has enabled to significantly increase production to ensure sustained inventory capacity and support the strong sales momentum expected in Japan.
• A Phase 4, 52-week, Open-label, Long-Term Study of Imeglimin in Japanese Type 2 Diabetic Patients with Renal Impairment conducted by Sumitomo Pharma is currently ongoing in Japan to strengthen TWYMEEG profile in this key subpopulation. Topline results are expected in mid-2024.

Rare metabolic diseases

• In February 2024, the European Patent Office (EPO) granted Poxel a new patent for PXL770, a novel, proprietary direct adenosine monophosphate kinase activator, which describes the use of PXL770 in the treatment of Autosomal-dominant polycystic kidney disease (ADPKD). This issued patent provides additional protection for PXL770 through 2041, with the potential for an additional 5 years through patent term extension. End of 2023, Poxel had been granted the same patent for PXL770 from the Japan Patent Office and the obtention is currently under review in other territories, including in the US.
• In adrenoleukodystrophy (ALD), PXL770 and PXL065 are prepared to advance, subject to additional financing, into two Phase 2a biomarker proof-of-concept (POC) clinical trials in male patients with adrenomyeloneuropathy (AMN), the most common ALD subtype. The studies will evaluate pharmacokinetics, safety and potential for efficacy, following 12-week treatment, based on relevant disease biomarkers, such as the effect on very long chain fatty acids (VLCFA), the characteristic plasma marker of the disease.

First Quarter 2024 Financial Update

As of March 31, 2024, cash and cash equivalents were EUR 2.5 million (USD 2.7 million)³, as compared to EUR 2,3 million (USD 2.6 million⁵) as of December 31, 2023. Net financial debt (excluding IFRS16 impacts and derivative debts) was EUR 47.4 million as of March 31, 2024, as compared to EUR 45.6 million as of December 31, 2023.

EUR (in thousands)	Q1 2024	Q4 2023
Cash	2,460	2,341
Cash equivalents	-